

4. Egger M, Juni P, Bartlett C, Hohenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic review? Empirical study. *Health Technol Assess*. 2003;7:1-76.
5. Moher D, Fortin P, Jadad AR, et al. Completeness of reporting of trials published in languages other than English: implications for the conduct and reporting of systematic reviews. *Lancet*. 1996;347:363-366.
6. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: epidemiology and diagnosis of *Helicobacter pylori* infection. *BMJ*. 2001;323:920-922.
7. Tsutsumi Y, Kanamori H, Yamoto H et al. Randomized study of *Helicobacter pylori* eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. *Ann Hematol*. 2005;84:807-811.
8. Ioannidis JPA, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. *CMAJ*. 2007;176:1091-1096.
9. Egger M, Davey-Smith G, Schneider M. Systematic reviews of observational studies. In: Egger M, Davey-Smith G, Altman DG, eds. *Systematic Reviews in Health Care. Meta-Analysis in Context*. 2nd Ed. London, United Kingdom: BMJ Books; 2001:211-227.

Response

A case of rich fruit

We thank Mark Crowther and his colleagues for the comments that they have made on our paper.¹ While we welcome their opinions, it is worth noting that systematic reviews and meta-analyses are areas where opinions differ, controversy remains, and comments on published work are common.

Their first point is that our search strategy was incomplete. They observe that a search using both text words and MeSH headings inclusive of conference abstracts results in an increased yield. It is unknown, however, if any of these studies would have been incorporated given our stringent inclusion criteria.

Secondly, Crowther and his colleagues state that our exclusion criteria may have led to bias. While these criteria were clearly delineated and judged by the authors to be clinically and epidemiologically appropriate, we acknowledge the restrictions they may have placed on our review, including the preclusion of potentially valuable data from studies published in non-English language journals and those using serological diagnoses. The former criterion was not possible given our available resources. The latter may have excluded some high-quality studies, but its removal would likely have resulted in the inclusion of many studies of lower quality; the sensitivity and specificity ranges of the enzyme-linked immunosorbent assay (ELISA) test are greater than for the ¹³C-UBT test and do not discriminate between patients with active infection and those whose infection has been eradicated.²

Their third point relates to homogeneity. We did have reservations about quantitatively synthesizing data because of the heterogeneity of results. However, we thought the studies to be sufficiently similar in scope to justify the pooling of their results. While visual inspection of the funnel plot (Stasi et al, Figure 2) does not show the perfect inverted V consistent with the absence of publication bias, the figure does show some decrease in spread with decreasing standard error. It would be implausible to think that a review such as this would be entirely free of bias. The heterogeneity noted is likely to be the result of small sample sizes (and in this analysis many studies are small) and biologic factors. Importantly, our exploration of this variability uncovered the striking correlation between country-specific infection prevalence and response rate illustrated in Figure 4.¹

We defend our use of the DerSimonian-Laird method to pool data across studies. Crowther and his colleagues suggest that this method increases the weight given to large observational studies, which may be more susceptible to bias. As a random-effects computation, it gives greater weight to smaller studies than conventional fixed-effects methods.³ Like most pooling methods, the DerSimonian-Laird method does partly weight studies by sample size, which we feel is appropriate. Although it is possible for large-scale observational studies to be susceptible to greater bias, this tendency is largely based on the methodology used, which was controlled for by the threshold established by our inclusion criteria. Furthermore, our investigation dealt almost exclusively with studies of small numbers of patients within a single center, a situation in which random fluctuation assumes a greater, potentially more dangerous role in impacting results.

In summary, we believe the methodology for our systematic review to be sound and support its finding of *Helicobacter pylori* eradication as a viable, noninvasive, and low-cost treatment for ¹³C-UBT-positive adults with immune thrombocytopenia, particularly in countries with a high prevalence of infection pending the outcome of large-scale randomized trials.

Ameet Sarpatwari, Jodi B. Segal, James B. Bussel, Roberto Stasi, and John Osborn

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Ameet Sarpatwari, Department of Public Health and Primary Care, University of Cambridge, Forvie site, Robinson Way, Cambridge CB2 0SR United Kingdom; e-mail: avs31@medschl.cam.ac.uk.

References

1. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of *Helicobacter pylori* infection in patients with immune thrombocytopenic purpura: a systematic review. *Blood*. 2009;113:1231-1240.
2. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: epidemiology and diagnosis of *Helicobacter pylori* infection. *BMJ*. 2001;323:920-922.
3. Pettiti DB. *Meta-Analysis, Decision-Analysis, and Cost-Effective Analysis: Methods in Quantitative Synthesis in Medicine*. 2nd Ed. London, United Kingdom: Oxford University Press; 2001:117.

To the editor:

Differences between nasal and extranasal NK/T-cell lymphoma

We read with interest the results of the peripheral T-cell lymphoma (PTCL) classification project reported by Au et al, which stated that prognosis of extranodal natural killer (NK)/T-cell lymphoma (ENKL) of nasal origin is different from that of extranasal origin.¹ They further concluded these 2 subtypes of ENKL are different entities.

We principally agree with their conclusion, but the prognostic difference they pointed out needs further estimation. Our data on 150 ENKLs (123 nasal and 27 extranasal)² also demonstrate the same results if analyzed as a whole (Figure 1A). However, the proportion of localized versus advanced stage of disease is completely different